ArticleProceedings of the National Academy of Sciences of the United States of America2004
Erythropoietin both protects from and reverses experimental diabetic neuropathy.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 250 citations in OpenAlex.
- Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study.Journal of neurology, neurosurgery, and psychiatry · 2015Trial
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.Molecular medicine (Cambridge, Mass.) · 2013Trial
- A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2013Trial
- Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.Molecular medicine (Cambridge, Mass.) · 2012Trial
- Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.Current pain and headache reports · 2026Review
- Erythropoietin promotes cell proliferation in Neuro-2A mouse neuroblastoma cells.Biochemistry and biophysics reports · 2025Article
- The Physiologic Basis of Molecular Therapeutics for Peripheral Nerve Injury: A Primer.Journal of hand surgery global online · 2024Review
- Neuroprotective Potential of 20(S)-Ginsenoside Rg3 Against the Progression of Diabetic Neuropathy: Experiments on Rat Sciatic Nerve.Journal of clinical practice and research · 2023Article
- Neuron-Schwann cell interactions in peripheral nervous system homeostasis, disease, and preclinical treatment.Frontiers in cellular neuroscience · 2023Review
- Locally Applied Repositioned Hormones for Oral Bone and Periodontal Tissue Engineering: A Narrative Review.Polymers · 2022Review
- Schwann cells expressing nociceptive channel TRPA1 orchestrate ethanol-evoked neuropathic pain in mice.The Journal of clinical investigation · 2019Article
- Neuroactive Steroids and Sex-Dimorphic Nervous Damage Induced by Diabetes Mellitus.Cellular and molecular neurobiology · 2019Review
- Polyphenols of marine red macroalgaHeliyon · 2019Article
- Erythropoietin and Friedreich Ataxia: Time for a Reappraisal?Frontiers in neuroscience · 2019Review
- Regulatable Transgene Expression for Prevention of Chemotherapy-Induced Peripheral Neuropathy.Molecular therapy. Methods & clinical development · 2017Article
- Erythropoietin enhanced recovery after peripheral nerve injury.Neural regeneration research · 2017Article
- Erythropoietin accelerates functional recovery after moderate sciatic nerve crush injury.Muscle & nerve · 2017Article
- In vivo optogenetic activation of NaJournal of neurophysiology · 2017Article
- Plant-Produced Asialo-Erythropoietin Restores Pancreatic Beta-Cell Function by Suppressing Mammalian Sterile-20-like Kinase (MST1) and Caspase-3 Activation.Frontiers in pharmacology · 2017Article
- Erythropoietin Enhanced Recovery After Traumatic Nerve Injury: Myelination and Localized Effects.The Journal of hand surgery · 2016Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythropoietin (EPO) possesses generalized neuroprotective and neurotrophic actions. We tested the efficacy of recombinant human EPO (rhEPO) in preventing and reversing nerve dysfunction in streptozotocin (STZ)-induced diabetes in rats. Two days after STZ [60 mg/kg of body weight (b.w.), i.p.], diabetic animals were administered rhEPO (40 microg/kg of b.w.) three times weekly for 5 weeks either immediately (preventive) before or after a 5-week delay (therapeutic) after induction of hyperglycemia or at a lower dose (8 microg/kg of b.w. once per week) for 8 weeks (prolonged). Tail-nerve conduction velocities (NCV) was assessed at 5 and 11 weeks for the preventive and therapeutic schedule, respectively. Compared to nondiabetic rats, NCV was 20% lower after 5 weeks in the STZ group, and this decrease was attenuated 50% by rhEPO. Furthermore, the reduction of Na(+),K(+)-ATPase activity of diabetic nerves (by 55%) was limited to 24% in the rhEPO-treated group. In the therapeutic schedule, NCV was reduced by 50% after 11 weeks but by only 23% in the rhEPO-treated group. rhEPO treatment attenuated the decrease in compound muscle action potential in diabetic rats. In addition, rhEPO treatment was associated with a preservation of footpad cutaneous innervation, as assessed by protein gene product 9.5 immunostaining. Diabetic rats developed alterations in mechanical and thermal nociception, which were partially reversed by rhEPO given either in a preventative or therapeutic manner. These observations suggest that administration of rhEPO or its analogues may be useful in the treatment of diabetic neuropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.